Oaktree Acquisition Corp. III Life Sciences
OACCW
NASDAQ Global Market0.88
USD
-0.17
- -
CIK
0002029769
ISIN
KYG6717R1121
CUSIP
G6717R112
Return %
Stock
S&P500
1Y
13.64
18.02
3Y
13.64
64.11
5Y
13.64
72.15
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Zaid Pardesi
- Full Time Employees
- 1,500
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 333 South Grand Avenue Los Angeles CA United States of America 90071
- IPO Date
- Oct 6, 2025
- CIK
- 0002029769
- Website
- oaktreeacquisitioncorp.com
- Similar Companies
- Business
- Oaktree Acquisition Corp. III Life Sciences operates as a blank-check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses in the life sciences sector; it targets North American, British or European companies in biopharmaceuticals, medical devices, diagnostics and specialized healthcare services. The company offers no current products or services beyond its SPAC structure, which provides up to $192 million in IPO proceeds held in trust, private placement units to its sponsor and warrants exercisable at $11.50 per share; its securities trade separately as Class A ordinary shares (OACC), warrants (OACCW) and units (OACCU) on Nasdaq following unit separation in December 2024. Sponsored by an affiliate of Oaktree Capital Management, L.P., with $205 billion in assets under management as of September 2024 and approximately $5 billion committed to 51 life sciences investments since 2013, the SPAC leverages a 12-person dedicated life sciences team with expertise in healthcare equity, credit, investment banking and medicine. Founded in 2024 and headquartered at 333 South Grand Avenue, 28th Floor, Los Angeles, California, it follows Oaktree-sponsored SPACs that merged with Hims & Hers Health in 2021 and Alvotech in 2022. Recent developments include pricing a $175 million IPO in October 2024 upsized to $192 million with full underwriter participation from Jefferies LLC, Citigroup Global Markets Inc. and UBS Investment Bank; completing the offering on October 25, 2024, with 17.5 million public units at $10 each plus 550,000 sponsor private placement units; and announcing separate trading of shares and warrants commencing December 16, 2024, with a 24-month deadline to complete a business combination by October 25, 2026.